Screener
Bausch + Lomb BLCO Surgical — Operating Income (Loss)
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch + Lomb in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Bausch + Lomb’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001860742-26-000088
| (in millions) | Vision Care / Three Months Ended June 30, 2026 | Vision Care / Three Months Ended June 30, 2025 | Pharmaceuticals / Three Months Ended June 30, 2026 | Pharmaceuticals / Three Months Ended June 30, 2025 | Surgical / Three Months Ended June 30, 2026 | Surgical / Three Months Ended June 30, 2025 | Total / Three Months Ended June 30, 2026 | Total / Three Months Ended June 30, 2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of other revenues | — | — | — | 2 | — | — | ||
| Selling, general and administrative | 247 | 243 | 149 | 154 | 80 | 73 | ||
| Research and development | 17 | 11 | 27 | 12 | 12 | 12 | ||
| Segment Profit | $229 | $209 | $89 | $37 | $17 | $2 | 335 | 248 |
| Corporate | (170) | (170) | ||||||
| Amortization of intangible assets | (57) | (67) | ||||||
| Other expense, net | (25) | (22) | ||||||
| Operating income (loss) | 83 | (11) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Bausch + Lomb's surgical — operating income (loss)?
- Bausch + Lomb (BLCO) reported surgical — operating income (loss) of $17M in Q2 2026.
- How has Bausch + Lomb's surgical — operating income (loss) changed year-over-year?
- Bausch + Lomb's surgical — operating income (loss) increased by 750.0% year-over-year, from $2M to $17M.
- What is the long-term trend for Bausch + Lomb's surgical — operating income (loss)?
- Over 4 years (2021 to 2025), Bausch + Lomb's surgical — operating income (loss) has grown at a -30.0% compound annual growth rate (CAGR), from $75M to $18M.
- What does surgical — operating income (loss) mean?
- Calculated as the surgical segment's total revenue minus its operating expenses, including cost of goods sold, R&D, and SG&A. This metric provides a clear view of the core profitability of the surgical business before interest and taxes. It is the primary benchmark for evaluating the operational success of the segment's business model.
Ask your AI about Bausch + Lomb's surgical — operating income (loss).
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude